Politics

Tracking how politics and policy influence health care and medicine. To get the latest delivered to your inbox, sign up for our free D.C. Diagnosis newsletter. And subscribe to STAT+ for inside intelligence on the intersection of Capitol Hill and the life sciences.

Politics Nicholas Florko

After nearly 4 years of deliberation, FDA punts on how to regulate CBD

The FDA is giving up on trying to figure out a way to regulate CBD on its own, and formally calling on Congress for help.

Read The Story

Politics Rachel Cohrs

The unexpected alliance lobbying for Medicare to pay for new obesity drugs

Politics Matthew Perrone — Associated Press

New lawsuits target state restrictions on abortion pills

Politics John Wilkerson

The 4 biggest questions about the FDA’s forthcoming changes to accelerated approvals

Politics Jonathan Wosen

Liquid-biopsy firm Grail is spending more than ever lobbying Congress

All Coverage

Politics Sarah Owermohle

Health groups like AHA, PhRMA channeled millions into end-of-year legislative debates

Politics Rachel Cohrs

PhRMA terminates lobbying contract with White House official’s brother

Politics Sarah Owermohle

‘Hot mess’: Abortion pills at pharmacies could face legal quagmires, especially in restrictive states

Politics Rachel Cohrs

HHS needs better oversight of research that alters pathogens, government watchdog says

Business Tara Bannow

Hip and knee replacements go better when performed by high-volume surgeons, new study finds

First Opinion Paul Hastings

Biopharma leaders helped save democracy. Now what?

Politics John Wilkerson

Congressional Medicare advisers warn of higher drug prices, despite new price negotiation

Politics Sarah Owermohle

Biden Covid adviser David Kessler to exit as pandemic response winds down

Insurance Bob Herman

Oscar Health’s CEO on post-hype health insurance and finally turning a profit

Politics John Wilkerson

With the FTC’s more expansive approach to antitrust, PBMs are in the crosshairs

Politics John Wilkerson

Medicare paves the way for CAR-T in doctors offices

Politics Rachel Cohrs

HHS will seek more input on its new Medicare drug price negotiations

Politics Rachel Cohrs

Will America’s public health reckoning ever come?

Hospitals Rachel Cohrs

HHS will decide how to resolve $1 billion in payments for 340B hospitals

Politics Sarah Owermohle

Still fuming over the federal Covid response, Republicans redirect the House coronavirus committee

Politics Sarah Owermohle

Rep. Jason Smith and the other Republicans leading health policy in the House

Politics Rachel Cohrs

3 drug pricing issues to watch in 2023

Politics Sarah Owermohle

Priorities pile up for HHS, FDA, CMS, NIH, and other health agencies

The Aduhelm Files Damian Garde and Rachel Cohrs

In wake of House investigation, 5 burning questions for FDA, Biogen, and Alzheimer’s treatments

The Aduhelm Files Rachel Cohrs, Adam Feuerstein and Damian Garde

FDA, Biogen, and an Alzheimer’s drug approval: 8 key takeaways from congressional investigation

The Aduhelm Files Rachel Cohrs

‘Rife with irregularities’: Congressional investigation reveals FDA’s approval of Aduhelm marked by secret discussions, breaches of protocol

The Aduhelm Files Damian Garde and Adam Feuerstein

Seeking maximum profits, Biogen set an ‘unjustifiably high price’ for Alzheimer’s treatment, investigation finds

Health Sarah Owermohle

New FDA guidance explains that Plan B is not an abortion pill

D.C. Diagnosis Rachel Cohrs

Politics

After nearly 4 years of deliberation, FDA punts on how to regulate CBD

The unexpected alliance lobbying for Medicare to pay for new obesity drugs

New lawsuits target state restrictions on abortion pills

The 4 biggest questions about the FDA’s forthcoming changes to accelerated approvals

Liquid-biopsy firm Grail is spending more than ever lobbying Congress

All Coverage

Health groups like AHA, PhRMA channeled millions into end-of-year legislative debates

PhRMA terminates lobbying contract with White House official’s brother

‘Hot mess’: Abortion pills at pharmacies could face legal quagmires, especially in restrictive states

HHS needs better oversight of research that alters pathogens, government watchdog says

Hip and knee replacements go better when performed by high-volume surgeons, new study finds

Biopharma leaders helped save democracy. Now what?

Congressional Medicare advisers warn of higher drug prices, despite new price negotiation

Biden Covid adviser David Kessler to exit as pandemic response winds down

Oscar Health’s CEO on post-hype health insurance and finally turning a profit

With the FTC’s more expansive approach to antitrust, PBMs are in the crosshairs

Medicare paves the way for CAR-T in doctors offices

HHS will seek more input on its new Medicare drug price negotiations

Will America’s public health reckoning ever come?

HHS will decide how to resolve $1 billion in payments for 340B hospitals

Still fuming over the federal Covid response, Republicans redirect the House coronavirus committee

Rep. Jason Smith and the other Republicans leading health policy in the House

3 drug pricing issues to watch in 2023

Priorities pile up for HHS, FDA, CMS, NIH, and other health agencies

In wake of House investigation, 5 burning questions for FDA, Biogen, and Alzheimer’s treatments

FDA, Biogen, and an Alzheimer’s drug approval: 8 key takeaways from congressional investigation

‘Rife with irregularities’: Congressional investigation reveals FDA’s approval of Aduhelm marked by secret discussions, breaches of protocol

Seeking maximum profits, Biogen set an ‘unjustifiably high price’ for Alzheimer’s treatment, investigation finds

New FDA guidance explains that Plan B is not an abortion pill

After nine months, an update on NIH’s long Covid research

You've been selected! STAT+ for less than $2/day

Subscribe to STAT+ for less than $2 per day